Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A in-patient, open-label, four-period, four-treatment, one-sequence, crossover phase I trial of OPNT-002 for the treatment of alcohol use disorder

Next Previous
X
Search
Trial Profile

A in-patient, open-label, four-period, four-treatment, one-sequence, crossover phase I trial of OPNT-002 for the treatment of alcohol use disorder

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Alcoholism
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Nov 2019 According to an Opiant Pharmaceuticals media release, this study is nearing completion.
    • 19 Jul 2017 Results published in an Opiant Pharmaceuticals Media Release.
    • 19 Jul 2017 According to an Opiant Pharmaceuticals media release, This study was conducted under a clinical trial agreement between Opiant and the National Institute of Drug Abuse (NIDA), a division of the National Institutes of Health (NIH).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top